The platform technology relates to drug and vaccine design through mimicking alpha helical segments of proteins using small molecules that constitute modular assemblies of the smallest known alpha helices. 30% of all protein structure is alpha helical. Frequently, alpha helical regions of proteins mediate protein function through interactions with other proteins, DNA or RNA. Usually only 2 to 4 helical turns are involved in such interactions. This technology focuses on the shortest known alpha helix, stabilized by the technology to maintain structure in water and to withstand unwinding even by strong protein denaturing conditions (e.g. 8M guanidine).

UniQuest Contact: 

Stephen Earl

Director, Commercialisation – Life Sciences
Mobile phone: 
+61 421 780 689
Work phone: 
+61 (7) 3365 4037